Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.
Susannah Murphy, DPhil, MA, MSc
Advertisement
Dr Murphy is an associate professor in the Department of Psychiatry at the University of Oxford. Murphy has received consultancy fees from Zogenix, Sumitomo Dainippon Pharma, UCB Pharma, and Janssen Pharmaceuticals. She holds grant income from UCB Pharma, Janssen Pharmaceuticals, and ADM.
Articles by Susannah Murphy, DPhil, MA, MSc
Advertisement
Latest Updated Articles
When the Fog Doesn’t Lift: Targeting Cognitive Dysfunction in DepressionPublished: March 24th 2025 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Post-Hoc Analysis: Ingrezza 40 mg Leads to Clinically Meaningful Improvements in Tardive Dyskinesia Symptoms
2
Evidence-Based Psychotherapy and Psychopharmacology for Mood Disorders: A Conversation With Holly A. Swartz, MD
3
Can the Initial Antipsychotic Influence Years of Weight Gain?
4
Accessory to War
5
